Travere Therapeutics, Inc. (TVTX) P/E Ratio History
Deep ValueTrading at -105.1x · 0th percentile of 5-year range · Significant discount to historical valuation · Data 2015–2016
Loading P/E history...
P/E Ratio Analysis
As of June 28, 2026, Travere Therapeutics, Inc. (TVTX) trades at a price-to-earnings ratio of -105.1x, with a stock price of $58.85 and trailing twelve-month earnings per share of $-0.23.
The current P/E is 910% below its 5-year average of 13.0x. Over the past five years, TVTX's P/E has ranged from a low of 8.4x to a high of 15.1x, placing the current valuation at the 0th percentile of its historical range.
Compared to the Healthcare sector median P/E of 23.0x, TVTX trades at a 556% discount to its sector peers. The sector includes 231 companies with P/E ratios ranging from 0.0x to 191.4x.
Relative to the broader market, TVTX trades at a notable discount to the S&P 500 median P/E of 25.3x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our TVTX DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
TVTX Cross-Benchmark Valuation
How does the current P/E compare to sector peers and the broader market?
TVTX P/E vs Peers
Commercial Rare Disease Biopharma peers sorted by market cap
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $4B | 11.1 | - | +68% | |
| $7B | 10.9Lowest | - | +264% | |
| $11B | 54.4 | - | +128% | |
| $39B | 125.1 | - | +207% | |
| $125B | 32.1 | 3.87Best | +837%Best | |
| $11B | 32.8 | - | -19% |
Lower P/E can signal a discount or weaker growth expectations; PEG adds growth context.
TVTX Historical P/E Data (2015–2016)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Period End | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2016 Q2 | - | $17.81 | $1.26 | 14.1x | +8% |
| FY2016 Q1 | - | $13.66 | $0.91 | 15.1x | +16% |
| FY2015 Q4 | - | $19.29 | $2.31 | 8.4x | -36% |
| FY2015 Q3 | Sep 30 2015 | $20.26 | $1.41 | 14.4x | +11% |
Average P/E for displayed period: 13.0x
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
11+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
TVTX — Frequently Asked Questions
Quick answers to the most common questions about buying TVTX stock.
What is TVTX's P/E ratio?
Travere Therapeutics, Inc. (TVTX) trailing twelve-month P/E ratio is -105.1x, based on TTM diluted EPS of $-0.23. The 5-year average P/E is 13.0x and the historical range spans 8.4x to 15.1x.
Is TVTX stock overvalued or undervalued?
TVTX trades at -105.1x P/E, below its 5-year average of 13.0x. At the 0th percentile of its historical range (8.4x–15.1x), the stock is priced at a discount to its own history.
Is TVTX stock expensive?
No, TVTX is not expensive on a historical basis. The current P/E of -105.1x is below the 5-year average of 13.0x and sits at the 0th percentile of its valuation range.
What is TVTX's historical P/E range?
Over the past 5 years, TVTX's P/E ratio has ranged from 8.4x to 15.1x, with a median of 14.4x and an average of 13.0x. The current P/E of -105.1x places the stock at the 0th percentile of this range. Full historical data spans 2015–2016.
How does TVTX's P/E compare to the S&P 500?
TVTX trades at -105.1x P/E versus the S&P 500 median of 25.3x. The 515% discount to the market suggests lower growth expectations or perceived higher risk.
How does TVTX's valuation compare to Healthcare peers?
Travere Therapeutics, Inc. P/E of -105.1x compares to the Healthcare sector median of 23.0x. The discount suggests lower growth expectations, weaker margins, or higher perceived risk relative to peers. See the peer comparison table on this page for ticker-by-ticker P/E and PEG.
What is TVTX's PEG ratio?
TVTX PEG ratio is N/A, based on a P/E of -105.1x and EPS growth of 86.3%. PEG normalises P/E by growth and helps compare stocks with different earnings trajectories.
What is TVTX's earnings yield?
TVTX earnings yield is N/A, the inverse of its -105.1x P/E ratio. Earnings yield represents the percentage of each dollar invested that the company earns. It can be compared directly to bond yields to assess relative attractiveness of stocks versus fixed income.